Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial-Reference-Cited by-同舟云学术

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Published:2012-05 Issue:9827 Volume:379 Page:1712-1720
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

van Vollenhoven Ronald F,Geborek Pierre,Forslind Kristina,Albertsson Kristina,Ernestam Sofia,Petersson Ingemar F,Chatzidionysiou Katerina,Bratt Johan

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

2. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial;Emery;Lancet,2008

3. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial;St Clair;Arthritis Rheum,2004

4. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis;Wessels;Arthritis Rheum,2007

5. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group;Lipsky;N Engl J Med,2000

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide;Reumatología Clínica;2024-07

2. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis;JAMA Network Open;2024-06-26

3. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17–18, 2022;Arthritis & Rheumatology;2024-05-28

4. Advances in non-biological drugs for the treatment of rheumatoid arthritis;Expert Opinion on Pharmacotherapy;2023-12-22

5. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study;Clinical Therapeutics;2023-09